Comparison of the effects of matrix metalloproteinase inhibitors on TNF-α release from activated microglia and TNF-α converting enzyme activity

Biomolecules and Therapeutics

Volumn 22, Issue 5, 2014, Pages 414-419

  Lee, Eun Jung ^a   Moon, Pyong Gon ^b   Baek, Moon Chang ^b   Kim, Hee Sun ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

Inflammation; Microglia; MMP inhibitor; TACE; TNF

Indexed keywords

ENZYME INHIBITOR; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GELATINASE B; MATRIX METALLOPROTEINASE 8 INHIBITOR; MATRIX METALLOPROTEINASE 9 INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; MICROGLIA; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DOMAIN;

EID: 84908018333     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2014.099     Document Type: Article

References (26)

1. Aggarwal, B. B. (2003) Signaling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745-756.
2. Agrawal, S. M., Lau, L. and Yong V. W. (2008) MMPs in the central nervous system: where the good guys go bad. Semin. Cell Dev. Biol. 19, 42-51.
3. Asai, M., Hattori, C., Szabó, B., Sasagawa, N., Maruyama, K., Tanuma, S. and Ishiura, S. (2003) Putative function of ADAM9, ADAM10, and ADAM17 as APP α-secretase. Biochem. Biophys. Res. Commun. 301, 231-235.
4. Bahia M. S. and Silakari O. (2010) Tumor necrosis factor alpha converting enzyme: an encouraging target for various inflammatory disorders. Chem. Biol. Drug Des. 75, 415-443.
5. Black, R. A., Rauch, C. T. Kozlosky, C. J. Peschon, J. J. Slack, J. L. Wolfson, M. F. Castner, B. J. Stocking, K. L. Reddy P. Srinivasan, S. Nelson, N. Boiani, N. Schooley K. A. Gerhart M. Davis, R. Fitzner, J. N. Johnson, R. S. Paxton, R. J. March, C. J. and Cerretti, D. P. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729-733.
6. Bocchini, V., Mazzolla, R., Barluzzi, R., Blasi, E., Sick, P. and Kettenmann, H. (1992) An immortalized cell line expresses properties of activated microglial cells. J. Neurosci. Res. 31, 616-621.
7. Candelario-Jalil, E., Yang, Y. and Rosenberg, G. A. (2009) Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158, 983-994.
8. Dev, R., Srivastava, P. K., Iyer, J. P., Dastidar, S. G. and Ray, A. (2010) Therapeutic potential of matrix metalloprotease inhibitors in neuropathic pain. Expert Opin. Investig. Drugs 19, 455-468.
9. Gearing, A. J., Beckett, P., Christodoulou, M., Churchill, M., Clements, J..M., Crimmin, M., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., Leber, T. M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomasv W., Wells, G., Wood, L. M. and Woolley, K. (1995) Matrix metalloproteinases and processing of pro-TNF-alpha. J. Leukoc. Biol. 57, 774-777.
10. Hu, J., Van den, Steen P. E., Sang, Q. X. A. and Opdenakker, G. (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Dicsov. 6, 480-498.
11. Javaid, M. A., Abdallah, M. N., Ahmed, A. S. and Sheikh, Z. (2013) Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview. Acta Neurol. Belg. 113, 381-390.
12. Kataoka, H. (2009) EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J. Dermatol. Sci. 56, 148-153.
13. Lee, E. J., Woo, M. S., Moon, P. G., Baek, M. C., Choi, I. Y., Kim, W. K., Junn, E. and Kim, H. S. (2010) α-Synuclein activates microglia by inducing the expressions of matrix metalloproteases and the subsequent activation of protease-activated receptor-1. J. Immunol. 185, 615-623.
14. Lee, E. J., Han, J. E., Woo, M. S., Shin, J. A., Park, E. M., Kang, J. L., Moon, P. G., Baek, M. C., Son, W. S., Ko, Y. T., Choi, J. W. and Kim, H. S. (2014) Matrix metalloproteinase-8 plays a pivotal role in neuroinflammation by modulating TNF-α activation. J. Immunol. 193, 2384-2393.
15. Li, N. G., Tang, Y. P., Duan, J. A. and Shi, Z. H. (2014) Matrix metalloproteinase inhibitors: a patent review (2011 - 2013). Expert Opin. Ther. Pat. 24, 1039-1052.
16. Mayhan, W. G. (2002) Cellular mechanisms by which tumor necrosis factor-a produces disruption of the blood-brain barrier. Brain Res. 927, 144-152.
17. McCoy, M. and Tansey, M. G. (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 5, 45.
18. Minond, D., Cudic, M., Bionda, N., Giulianotti, M., Maida, L., Houghten, R. A. and Fields, G. B. (2012) Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates. J. Biol. Chem. 287, 36473-36487.
19. Morancho, A., Rosell, A., García-Bonilla L. and Montaner J. (2010) Matrix metalloproteinase and stroke infarct size: role for anti-inflammatory treatment. Ann. N. Y. Acad. Sci. 1207, 123-133.
20. Moss, M. L., Jin, S. L., Milla, M. E., Bickett, D. M., Burkhart, W., Carter, H. L., Chen, W. J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., Kost, T. A., Lambert, M. H., Leesnitzer, M. A., McCauley, P., McGeehan, G., Mitchell, J., Moyer, M., Pahel, G., Rocque, W., Overton, L. K., Schoenen, F., Seaton, T., Su, J. L. and Becherer, J. D. (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385, 733-736
21. Moss, M. L., Sklair-Tavron, L. and Nudelman, R. (2008) Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 4, 300-309.
22. Rosenberg, G. A. (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 8, 205-216.
23. Tian, L., Ma, L., Kaarela, T. and Li, Z. (2012) Neuroimmune crosstalk in the central nervous system and its significance for neurological diseases. J. Neuroinflammation 9, 155.
24. Verma, R. P. and Hansch, C. (2007) Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs. Bioorg. Med. Chem. 15, 2223-2268
25. Verslegers, M., Lemmens, K., Hove, I. V. and Moons, L. (2013) Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system. Prog. Neurobiol. 105, 60-78.
26. Woo, M. S., Park, J. S., Choi, I. Y., Kim, W. K. and Kim, H. S. (2008) Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J. Neurochem 106, 770-780.